| Literature DB >> 26014387 |
Christoffer Laustsen1, Esben Søvsø Szocska Hansen1,2, Uffe Kjaergaard1, Lotte Bonde Bertelsen1, Steffen Ringgaard1, Hans Stødkilde-Jørgensen1.
Abstract
PURPOSE: Our aim was to determine the quantitative reproducibility of metabolic breakdown products in the kidney following intravenous injection of hyperpolarized [1-(13)C]pyruvate and secondly to investigate the metabolic effect on the pyruvate metabolism of oral sucrose load using dissolution dynamic nuclear polarization. By this technique, metabolic alterations in several different metabolic related diseases and their metabolic treatment responses can be accessed.Entities:
Keywords: MRI; MRS; hyperpolarization; kidney; renal metabolism; sucrose
Mesh:
Substances:
Year: 2015 PMID: 26014387 PMCID: PMC4736686 DOI: 10.1002/mrm.25692
Source DB: PubMed Journal: Magn Reson Med ISSN: 0740-3194 Impact factor: 4.668
Figure 1Study design illustration, endogastric regular Coca Cola administration was performed after the second fasted hyperpolarized examination (20 min). The initial blood gas measurement was followed by blood glucose measurements every 10 min and hyperpolarized [1‐13C]pyruvate MRS experiments every 20 min. The experiment is completed with a final blood gas measurement.
Figure 2Illustrative 1H anatomical image with two kidney ROIs and a single voxel outline (1.25 x 1.25 x 1 cm3) (A) for the spectrum (B). 1H anatomical image overlay showing the individual metabolic maps of 13C lactate (183.2 ppm), alanine (176.5 ppm), pyruvate (170.6 ppm) and bicarbonate (160.9 ppm), showing a high metabolic conversion in the healthy kidneys, images are individually log scaled.
Summary results from arterial blood gas levels obtained before and after glucose administration. Significant results (p<0.05) are marked with *.
| Pre | Difference | Post | |
|---|---|---|---|
| pH | 7.49±0.10 | (p=0.01) | 7.38±0.10 * |
| pO2 (kPa) | 40.5±7.13 | (p=0.08) | 36.23±9.83 |
| pCO2 (kPa) | 4.87±1.0 | (p=0.02) | 6.16±1.33 * |
| Lac (mmol/L) | 0.7±0.16 | (p=0.01) | 2.23±0.38 * |
| Na (mmol/L) | 134.50±1.29 | (p=0.06) | 133.75±0.96 |
| K (mmol/L) | 3.98±0.3 | (p=0.10) | 3.68±0.17 |
| Ca (mmol/L) | 1.34±0.03 | (p=0.22) | 1.33±0.04 |
| Cl‐ (mmol/L) | 101.50±1.29 | (p=0.04) | 99.75±1.50 * |
Figure 3Lactate‐to‐pyruvate ratio as function of time (A); alanine‐to‐pyruvate ratio as function of time (B); pyruvate‐to‐total‐carbon ratio as function of time (C); bicarbonate‐to‐pyruvate ratio as function of time (D); blood glucose as function of time (E); CO2 as function of time (F). Significant differences (P < 0.05) between the initial control measurements and the results following endogastric soft drink infusion are marked with *. Error bars represent standard error of mean (SEM).
Figure 4Blood glucose as function of time (A); Blood lactate as function of time (B); pO2 as function of time (C); CO2 as function of time (D).
Within subjects SD in the fasted state, between subjects SD in the fasted state and Intraclass Correlation (ICC) in the fasted state.
| Lactate | Alanine | Pyruvate | Bicarbonate | |
|---|---|---|---|---|
| Within subject SD | 0.0048 | 0.0026 | 0.0072 | 0.0005 |
| Between subject SD | 0.027 | 0.011 | 0.029 | 0.002 |
| ICC | 0.97 | 0.95 | 0.94 | 0.96 |